21 September 2026
CagriSema tops tirzepatide on weight in diabetes trial
Topline REIMAGINE 5: 12.4% vs 9.1% at 60 weeks on the efficacy estimand.
The full briefing is in the app.
21 September 2026
Topline REIMAGINE 5: 12.4% vs 9.1% at 60 weeks on the efficacy estimand.
The full briefing is in the app.